I am a molecular oncology researcher with a strong interest in understanding the mechanisms by which cancer evades innovative therapies, particularly targeted therapies and immunotherapy. My research focuses on unraveling both intrinsic and acquired resistance mechanisms to targeted treatments, aiming to identify the molecular alterations and adaptive pathways that enable tumor cells to escape therapeutic pressure. By dissecting these resistance processes, I strive to propose novel strategies to overcome them, including rational combination therapies designed to restore drug sensitivity. My research efforts are dedicated to the early identification of patients who are likely to respond—or not respond—to specific therapies. In particular, my work has focused on identifying predictive biomarkers that can anticipate treatment response, allowing for better patient stratification and more personalized therapeutic approaches. Through the integration of molecular profiling and clinical data, I aim to refine precision medicine strategies and optimize therapeutic decision-making. By bridging molecular oncology research with clinical applications, my goal is to advance personalized cancer treatment, ensuring that each patient receives the most effective and tailored therapeutic approach.